文献速递血栓与止血

尿液蛋白质组学揭示可用于早期识别儿童激素耐药型免疫性血小板减少症中利妥昔单抗获益者的候选生物标志物

Urine proteomics uncovers biomarker candidates for early identifying rituximab beneficiaries in paediatric steroid-resistant immune thrombocytopenia.
PubMed 文献 · Br J Haematol · 2025-08-08

该研究分析37例激素耐药型免疫性血小板减少症患儿(17例利妥昔单抗应答者、20例无应答者)及40例健康对照的尿液样本,采用发现-验证蛋白质组学流程。发现队列治疗前鉴定78个差异蛋白、治疗后67个差异蛋白;验证KLK6和FUBP1预测利妥昔单抗应答的AUC为0.98(灵敏度1.00、特异度0.85)。

要点

  • 治疗前RTX-R组与体液免疫和补体激活相关,RTX-NR组与细胞免疫和糖酵解关联更强。
  • KLK6和FUBP1预测利妥昔单抗应答的AUC为0.98,灵敏度1.00、特异度0.85。
  • HK1、FUBP1、LAIR2、CSTA和RPL12监测模型区分治疗后RTX-R与RTX-NR的AUC为1.00。

核心结论

  • 尿液蛋白质组学发现KLK6和FUBP1可作为预测儿童激素耐药型ITP患者利妥昔单抗应答的候选生物标志物,并增进了对利妥昔单抗机制的理解。

研究设计与样本

  • 研究分析37例激素耐药型ITP患者(17例利妥昔单抗应答者RTX-R、20例无应答者RTX-NR)及40例健康对照的尿液样本,采用发现-验证蛋白质组学流程。

主要发现

  • 发现队列中,治疗前鉴定78个差异蛋白,治疗后鉴定67个差异蛋白(数据非依赖采集DIA方法)。
  • 治疗前RTX-R组与体液免疫和补体激活相关,RTX-NR组与细胞免疫和糖酵解关联更强。
  • Mfuzz分析提示利妥昔单抗通过降低B细胞受体通路和脂质代谢、增强血小板活化发挥作用。
  • 验证KLK6和FUBP1预测利妥昔单抗应答的AUC为0.98,灵敏度1.00、特异度0.85。
  • HK1、FUBP1、LAIR2、CSTA和RPL12监测模型区分治疗后RTX-R与RTX-NR的AUC为1.00,灵敏度0.92、特异度0.95。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rituximab (RTX) is an effective treatment for children with steroid-resistant immune thrombocytopenia (ITP), but reliable biomarkers to predict its response early are lacking. We analysed urine samples from 37 steroid-resistant ITP patients-17 RTX responders (RTX-R) and 20 RTX non-responders (RTX-NR)-along with 40 healthy controls using a discovery-validation proteomics workflow. In the discovery cohort, we identified 78 differential proteins (DPs) before treatment and 67 DPs after treatment using the data-independent acquisition (DIA) approach. The RTX-R group was associated with humoral immunity and complement activation before treatment, while the RTX-NR group showed stronger connections to cellular immunity and glycolysis. The Mfuzz analysis indicated that RTX worked by reducing the B-cell receptor pathway and lipid metabolism while enhancing platelet activation. We validated two proteins (KLK6 and FUBP1) as candidate biomarkers for predicting RTX response through parallel reaction monitoring (PRM) technology, achieving an area under the curve (AUC) of 0.98, with a sensitivity of 1.00 and specificity of 0.85. A monitoring model with HK1, FUBP1, LAIR2, CSTA and RPL12 differentiated RTX-R from RTX-NR after treatment, yielding an AUC of 1.00, sensitivity of 0.92 and specificity of 0.95. Overall, these findings enhance our understanding of RTX mechanisms and support personalized therapy development for ITP.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Yu Y, Xie X, Chen Z, et al. Urine proteomics uncovers biomarker candidates for early identifying rituximab beneficiaries in paediatric steroid-resistant immune thrombocytopenia. Br J Haematol. 2025. PMID: 40781812. doi:10.1111/bjh.70072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。